nach oben

Journal of Neuro-Oncology

Erschienen in:

01.07.2007 | Clinical Study

Successful treatment of cancer-associated retinopathy with alemtuzumab

verfasst von: Ladan Espandar, Susan O’Brien, Charles Thirkill, Linda A. Lubecki, Bita Esmaeli

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

We herein report a patient with cancer-associated retinopathy who experienced multiple bouts of paraneoplastic retinopathy and optic neuropathy but responded to treatments with alemtuzumab and was able to maintain useful vision over the course of 8 years of follow-up.

Jacobson DM (1998) Paraneoplastic diseases of neuro-ophthalmologic interest. In: Miller NR, Newman N (eds) Walsh & Hoyts clinical neuro-ophthalmology, 5th edn. Williams and Wilkins, Baltimore, pp 2497–2551

Adamus G, Guy J, Schmied JL et al (1993) Role of anti-recoverin autoantibodies in cancer-associated retinopathy. Invest Ophthalmol Vis Sci 34:2626–2633PubMed

Thirkill CE, Tait RC, Tyler NK et al (1992) The cancer-associated retinopathy antigen is a recoverin-like protein. Invest Ophthalmol Vis Sci 33:2768–2772PubMed

Malik S, Furlan AJ, Sweeney PJ, Kosmorsky GS, Wong M (1992) Optic neuropathy: a rare paraneoplastic syndrome. J Clin Neuroophthalmol 12:137–141PubMed

Keltner JL, Thirkill CE (1998) Cancer-associated retinopathy vs recoverin-associated retinopathy. Am J Ophthalmol 126:296–302PubMedCrossRef

Luiz JE, Lee AG, Keltner JL, Thirkill CE, Lai EC (1998) Paraneoplastic optic neuropathy and autoantibody production in small-cell carcinoma of the lung. J Neuroophthalmol 18:178–181PubMed

de la Sayette V, Bertran F, Honnorat J, Schaeffer S, Iglesias S, Defer G (1998) Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor. Arch Neurol 55:405–408CrossRef

Thambisetty MR, Scherzer CR, Yu Z, Lennon VA, Newman NJ (2001) Paraneoplastic optic neuropathy and cerebellar ataxia with small cell carcinoma of the lung. J Neuroophthalmol 21:164–167PubMed

Browning AC, Amoaku WM, Vernon SA et al (2004) Cachexia and poor night vision. Lancet 363:1305PubMedCrossRef

10.

Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic nerve, and cancer cells. (1989) N Engl J Med 321:1589–1594

11.

Hohwy T, Bang K, Steiniche T, Peterslund NA, d_Amore F (2004) Alemtuzumab-induced remission of both severe paraneoplastic pemphigus and leukaemic bone marrow infiltration in a case of treatment-resistant B-cell chronic lymphocytic leukaemia. Eur J Haematol 73:206–209PubMedCrossRef

12.

Full prescribing information (PI) for Campath^®. www.campath.com

13.

Golay J, Cortiana C, Manganini M et al (2006) The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. Haematologica 91:322–330PubMed

14.

Ravandi F, Kantarjian H, Jones D, Dearden C, Keating M, O’Brien S (2005) Mature T-cell leukemias. Cancer 104:1808–1818PubMedCrossRef

15.

Busca A, Locatelli F, Lovisone E et al (2005) Treatment of severe refractory acute graft-versus-host disease of the gastrointestinal tract with campath-1H. Biol Blood Marrow Transplant 11:734–736PubMedCrossRef

16.

Wertheim MS, Ross AH, Tole DM. The use of Campath in severe peripheral ulcerative keratitis associated with Wegener’s granulomatosis. Eye Advance. Online publication, 7 April 2006; doi:10.1038/sj.eye.6702330

17.

Coles AJ, Cox A, Le Page E et al (2006) The window of therapeutic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy. J Neurol 253:98–108PubMedCrossRef

18.

Chalandon Y, Roosnek E, Mermillod B, Waelchli L, Helg C, Chapuis B (2006) Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study. Biol Blood Marrow Transplant 12:102–110PubMedCrossRef

19.

Keltner JL, Thirkill CE, Tyler NK et al (1992) Management and monitoring of cancer-associated retinopathy. Arch Ophthalmol 110:48–53PubMed

20.

Jacobson DM, Thirkill CE, Tipping SJ (1990) A clinical triad to diagnose paraneoplastic retinopathy. Ann Neurol 28:162–167PubMedCrossRef

21.

Kashiwabara K, Nakamura H, Kishi K et al (1999) Cancer-associated retinopathy during treatment for small-cell lung carcinoma. Intern Med 38:597–601PubMed

22.

Thirkill CE, Roth AM, Keltner JL (1987) Cancer-associated retinopathy. Arch Ophthalmol 105:372–375PubMed

23.

Keltner JL, Thirkill CE, Tyler NK et al (1992) Management and monitoring of cancer-associated retinopathy. Arch Ophthalmol 110:48–53PubMed

24.

Yoon YH, Cho EH, Sohn J, Thirkill CE (1999) An unusual type of cancer-associated retinopathy in a patient with ovarian cancer. Korean J Ophthalmol 13:43–48PubMed

25.

Murphy MA, Thirkill CE, Hart WM (1996) Paraneoplastic retinopathy: a novel autoantibody reaction associated with small cell lung carcinoma. J Neuroophthalmol 17:77–83

26.

Salgia R, Hedges TR, Rizk M et al (1998) Cancer-associated retinopathy in a patient with non-small-cell lung carcinoma. Lung Cancer 22:149–152PubMedCrossRef

27.

Thirkill CE, FitzGerald P, Sergott RC et al (1989) Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic-nerve, and cancer cells. N Engl J Med 321:1589–1594PubMedCrossRef

28.

Guy J, Aptsiauri N (1999) Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Arch Ophthalmol 117:471–477PubMed

29.

Brink H, Deutman A, Beex L (1997) Unusual retinal pigment epitheliopathy and choroidopathy in carcinomatosis: a rare case of cancer-associated retinopathy. Graefes Arch Clin Exp Ophthalmol 236:75CrossRef

Titel: Successful treatment of cancer-associated retinopathy with alemtuzumab
verfasst von: Ladan Espandar
Susan O’Brien
Charles Thirkill
Linda A. Lubecki
Bita Esmaeli
Publikationsdatum: 01.07.2007
Verlag: Kluwer Academic Publishers-Plenum Publishers
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2007
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-006-9326-7

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Successful treatment of cancer-associated retinopathy with alemtuzumab

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2007

Gliosarcoma with primitive neuroectodermal differentiation: case report and review of the literature

Malignant astroblastoma with rhabdoid morphology

Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells

Atypical papillary glioneuronal tumor

Successful treatment of intracranial ependymoma with leptomeningeal spread with systemic chemotherapy and intrathecal liposomal cytarabine in a two-year-old child

Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie